rosuvastatin/omega-3-acids ethyl esters (HCP1105)
/ Hanmi
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 16, 2015
Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD
(clinicaltrials.gov)
- P3 | N=270 | Recruiting | Sponsor: Hanmi Pharmaceutical Company Limited
New P3 trial • Cardiovascular • Coronary Artery Disease • Dyslipidemia • APOA1
1 to 1
Of
1
Go to page
1